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PoultryNewcastle disease (ND) remains a constant threat to poultry producers worldwide, in spite of the avail-
ability and global employment of ND vaccinations since the 1950s. Strains of Newcastle disease virus
(NDV) belong to the order Mononegavirales, family Paramyxoviridae, and genus Avulavirus, are con-
tained in one serotype and are also known as avian paramyxovirus serotype-1 (APMV-1). They are pleo-
morphic in shape and are single-stranded, non-segmented, negative sense RNA viruses. The virus has
been reported to infect most orders of birds and thus has a wide host range. Isolates are characterized
by virulence in chickens and the presence of basic amino acids at the fusion protein cleavage site. Low
virulent NDV typically produce subclinical disease with some morbidity, whereas virulent isolates can
result in rapid, high mortality of birds. Virulent NDV are listed pathogens that require immediate notiﬁ-
cation to the Ofﬁce of International Epizootics and outbreaks typically result in trade embargos. Protec-
tion against NDV is through the use of vaccines generated with low virulent NDV strains. Immunity is
derived from neutralizing antibodies formed against the viral hemagglutinin and fusion glycoproteins,
which are responsible for attachment and spread of the virus. However, new techniques and technologies
have also allowed for more in depth analysis of the innate and cell-mediated immunity of poultry to NDV.
Gene proﬁling experiments have led to the discovery of novel host genes modulated immediately after
infection. Differences in virus virulence alter host gene response patterns have been demonstrated. Fur-
thermore, the timing and contributions of cell-mediated immune responses appear to decrease disease
and transmission potential. In view of recent reports of vaccine failure frommany countries on the ability
of classical NDV vaccines to stop spread of disease, renewed interest in a more complete understanding of
the global immune response of poultry to NDV will be critical to developing new control strategies and
intervention programs for the future.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Despite the advances made in the diagnosis of and vaccination
for Newcastle disease since it was ﬁrst described in 1926, the dis-
ease continues to negatively impact poultry producers by infecting
birds worldwide (Alexander et al., 2012; Goldhaft, 1980). From
2006 to 2009 the most widespread animal diseases, in terms of
the number of countries affected, were rabies, Newcastle disease
(ND) and Bovine tuberculosis (Anonymous, 2011). ND ranked as
the fourth most important disease in terms of the number of live-
stock units lost for poultry species, behind highly pathogenic avian
inﬂuenza, infectious bronchitis, and lowly pathogenic avian
inﬂuenza (Anonymous, 2011). The disease is caused by only thevirulent strains of avian paramyxovirus serotype-1 (AMPV-1) and
APMV-1 is synonymous with Newcastle disease virus (NDV) (OIE,
2012). Strains are deﬁned as virulent if they (1) have three or more
basic amino acids at position 113–116 of the un-cleaved fusion
protein cleavage site (F0) with a phenylalanine at position 117,
or (2) obtain a intracerebral pathogenicity index (ICPI) value of
P0.7 in day-old chickens (Gallus gallus) (OIE, 2012). Failure to
demonstrate multiple basic amino acids necessitates an ICPI value
be obtained for the isolate.
NDV is known to infect over 236 species of birds (Kaleta and
Baldauf, 1988) and besides poultry species virulent NDV (vNDV)
strains are commonly found in pigeons and double crested cormo-
rants (Diel et al., 2012b; Kim et al., 2008; Pchelkina et al., 2013)
and occasionally in some other wild bird species (Kaleta and
Kummerfeld, 2012). Typically, the concern is that pigeons will
transmit their vNDV strains of genotype VIb to poultry (Abolnik
et al., 2004; Alexander and Parsons, 1986), however, poultry are
able to transmit their vNDV strains to pigeons, as well (Merino
et al., 2009). The incubation period and clinical disease observed
with a NDV infection depends on multiple factors. The typical
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fected with the vNDV, the immunity of the host to NDV and the
amount and strain of vNDV the host is exposed to (Alexander
and Senne, 2008).
The clinical signs observed upon infection will be non-speciﬁc
and can include depression, rufﬂed feathers, open mouth breath-
ing, hyperthermia, anorexia, listlessness and hypothermia before
death. In addition, since the lesions observed upon infection with
vNDV are not pathognomonic, other diseases such as highly path-
ogenic avian inﬂuenza, infectious laryngotracheitis and mycoplas-
mosis should be considered (Alexander and Senne, 2008).
However, if hemorrhage and necrosis of lymphoid tissues is pres-
ent, especially of the intestine, spleen and thymus, viscerotropic
vNDV should be suspected (Cattoli et al., 2011). Because layers re-
ceive multiple NDV vaccinations during their production cycle, and
thus have persistent immunity, they may not show signs of infec-
tion except a drop in egg production (Bwala et al., 2012; Cho et al.,
2008). Birds infected with neurotropic vNDV strains remain alert
prior to developing neurological signs such as torticollis, ataxia
or a wing or leg paralysis and gross lesions are usually absent (Cat-
toli et al., 2011).
All strains of Newcastle disease virus (NDV) belong to the order
Mononegavirales, family Paramyxoviridae, and genus Avulavirus,
are contained in one serotype and are also known as avian para-
myxovirus serotype-1 (APMV-1) (Alexander and Senne, 2008).
The virions are pleomorphic in shape, and consist of single-
stranded, non-segmented, negative sense RNA genomes (Miller
et al., 2010). There are at least three different genome lengths
(15,186, 15,192 or 15,198), with six genes that produce six struc-
tural proteins in a 30 to 50 order: nucleocapsid (N), phosphoprotein
(P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN) and
the RNA dependent RNA (large) polymerase (L). Editing of P pro-
duces at least one other protein, the V protein, which has anti-
interferon properties (Czegledi et al., 2006).
Even though all strains of NDV are contained in one serotype,
there are phylogenetic differences found when comparing genome
relatedness. Strains are divided into two classes, class I and class II,
with class II further divided into 16 genotypes (Diel et al., 2012a).
Class I viruses are typically isolated from wild birds and all re-
ported strains are of low virulence except for one strain, chicken/
Ireland/1990 (Alexander et al., 1992). Class II, genotype I NDV are
all of low virulence except for the vNDV that caused the ND out-
break in 1998 in Australia (Gould et al., 2001). Class II, genotype
II viruses contain NDV of low virulence, some of which (B1, LaSota,
VG/GA) are used as NDV vaccines, and vNDV that are not com-
monly isolated (Miller et al., 2010). NDV strains of class II, geno-
types III–IX, and XI–XVI are all virulent (Courtney et al., 2012;
Diel et al., 2012a). Isolates of class II, genotype X are of low viru-
lence and most often found in wild birds, but some have been iso-
lated from some poultry species (Diel et al., 2012a; Miller et al.,
2011).
While humoral immunity from vaccination is critical to ND con-
trol, another important aspect that is not a new concept, but is of-
ten neglected, is the differences in resistance to ND due to genetic
variation (Albiston and Gorrie, 1942). In addition, it is known that
there is a negative correlation between a primary antibody re-
sponse to NDV and favorable production traits (Lwelamira et al.,
2009). Genetic resistance to ND has been observed with various
lines within a breed for chickens (Cole and Hutt, 1961; Gordon
et al., 1971) and turkey (Tsai et al., 1992) and among breeds of
chickens (Hassan et al., 2004; King, 1996) and ducks (Shi et al.,
2011). Concerning this topic it is important to note that each New-
castle disease virus may be better adapted to grow in one species
versus another, like what is seen with PPMV1 (pigeon NDV) strains
in chickens (Pearson et al., 1987). Another example of this can be
seen with the variability in the bird infectious dose 50 of oneNDV for chickens, turkeys and ducks (Aldous et al., 2010). While
improving genetic resistance to ND through breeding more resis-
tant bird strains appears to be feasible, logistically it is very difﬁ-
cult due to the involvement of multifactorial components.
Perhaps when the efﬁciency of producing transgenic birds is im-
proved, more disease resistance breeds can be used for this pur-
pose (Zhang et al., 2012).
Another important factor for ND control in developing countries
is the lack of a ‘‘cold chain’’ or reliable source to keep the vaccines
at 4 C. Even the best live vaccine will not induce an immune re-
sponse if it is not viable due to improper storage during the distri-
bution process. Progress has been made with the thermostable I-2
strain of NDV and has been put into place in some developing
countries (Bensink and Spradbrow, 1999; Harrison and Alders,
2010; Illango et al., 2005; Nasser et al., 2000). Continued improve-
ment and utilization of thermostable NDV strains is necessary to
improve controls in countries where vNDV isolates are endemic
and the cold chain is unreliable.2. Innate immune response to NDV infection in poultry
The innate immune response comprises factors that exist prior
to the advent of infection, and are capable of exclusion or rapid re-
sponse to microbes. The primary components of innate immunity
of poultry are (1) physical and chemical barriers, such as feathers
and skin, epithelia and production of mucus; (2) phagocytic cells,
including macrophages and natural killer cells; (3) complement
proteins andmediators of inﬂammation; and (4) cytokines. Overall,
the innate immune response to virus infection is an immediate
reaction designed to control and inhibit virus growth and spread
and aid in developing pathogen-speciﬁc protection through the
adaptive immune response. The early reactions of the innate im-
mune system use germ-line encoded receptors, known as pattern
recognition receptors (PRR’s), which recognize evolutionarily con-
served molecular markers of infectious microbes, known as PAMP’s
(pathogen-associated molecular patterns). Recognition of PAMPs
by PRRs, either alone or in heterodimerization with other PRRs,
(toll-like receptors (TLR); nucleotide-binding oligomerization do-
main proteins (NOD); RNA helicases, such as retinoic acid-induc-
ible gene 1 (RIG-I) or MDA5; C-type lectins), induces intracellular
signals responsible for the activation of genes that encode for
pro-inﬂammatory cytokines, anti-apoptotic factors, and antimicro-
bial peptides. The virus is ﬁrst recognized by host sentinel proteins,
including TLR and NOD proteins, producing rapid signaling and
transcription factor activation that lead to production of soluble
factors, including interferon and cytokines, designed to limit and
contain viral replication.
NDV infection in vitro results in nitric oxide (NO) induction in
chicken heterophils and peripheral blood mononuclear cells, inter-
feron alpha (IFN-a) and beta (IFN-b) mRNA detection in macro-
phages, and gamma (IFN-c) mRNA production in peripheral
blood mononuclear cells (Ahmed et al., 2007; Sick et al., 2000,
1998). In addition, infection of chicken heterophils decreased the
ability to phagocytose bacteria, resulting in impaired heterophil
function, andmaking birds more susceptible to secondary infection
(Lam et al., 1996). Constitutive low-level expression of NO in the
vascular endothelium plays a beneﬁcial role in maintaining blood
vessel homeostasis, but high levels of NO produced by macro-
phages in response to pathogens can have toxic effects on the host
(Palmer et al., 1987).
In mammalian systems, such as cultured murine macrophages,
NDV induced both IFN-a and IFN-b (Hoss et al., 1989; Zawatzky
et al., 1991). The functional signiﬁcance of the interferon regula-
tory factor genes (IRF)-3 and IRF-7 was examined in mouse macro-
phages derived from deletion knock out (KO) animals (Wilden
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ceptibility of mouse macrophages to NDV infection. NDV replicated
better in IRF-3 KO than in IRF-7 KO macrophages. Furthermore,
early production of type I interferon at later time points, as op-
posed to high maximal levels, appears important for resistance to
NDV infection. Taken together, these results demonstrate a role
for IRF-3 in the innate anti-viral response to NDV of mouse
macrophages.
Using microarray systems to measure gene expression patterns
in chicken embryo ﬁbroblasts infected with vNDV, strain Texas GB,
Munir, et al. demonstrated increased IFN-a and IFN-b (Munir et al.,
2005). Stimulation of interferon resulted in the upregulation of
numerous interferon-stimulated genes (ISG), include the IFN in-
duced protein with tetratricopeptide repeats 4, retinoic acid and
IFN inducible 58 kDa protein (RI58), IFN-induced 56 kDa protein
(IFI-56K), IFN-a inducible protein P27-H, and signal transducer
and activator of transcription-1 (STAT-1a/b). Interestingly, in these
studies peak gene expression in vitro did not appear until 36 h post
infection (h.p.i.), unlike other studies that show earlier innate
expression.
Our in vitro studies conﬁrm those of others, demonstrating the
strong induction of the host response genes, IFN-a, IFN-b, interleu-
kin (IL)-1b and IL-6 in splenic leukocytes (Rue et al., 2011). Using
real-time RT-PCR of RNA isolated from NDV-infected splenocytes,
we have demonstrated that the vNDV strain, CA02, but not the len-
togenic LaSota virus, at 6 h.p.i. is capable of rapidly and strongly
inducing IFN-a, IFN-c, IL-6 and IL-1b, genes integral to a pro-
inﬂammatory response (Fig. 1). Unfortunately, since LaSota does
not reach the spleen but only replicates at the site of inoculation,
parallel in vivo experiments to compare the relative host response
to virulent and LaSota NDV strain of low virulence were not possi-
ble (Wakamatsu et al., 2006a,b). The observed differences in time
of cytokine expression between our studies and others may be ex-
plained by differences in the dose of virus used between the stud-
ies. The enhanced host response to vNDV, in conjunction with
severe pathological damage observed, is somewhat surprising con-
sidering that all NDV encode a gene, V, which functions to suppress
class I IFNs. However, this robust innate response to vNDV hasFig. 1. Real-time RT-PCR of NDV-CA02 and LaSota vaccine strain-infected chicken
splenocytes in vitro. Total RNA isolated from chicken splenocytes infected with
NDV, CA02 and LaSota, for 6 h was used for real-time RT-PCR using SYBR Green for
IFN-a, IFN-c, IL-1b and IL-6. Results were normalized against 28S rRNA and fold-
changes relative to mockinfected samples are shown. Open bar represents low
virulent LaSota and solid bar represents vNDV CA02 (CA02).been suggested as being deleterious to the host, and a possible
cause of the pathological effect (Rue et al., 2011). Regardless, it is
clear that NDV of low virulence stimulates a lower innate immune
responses compared with vNDV that induces signiﬁcantly higher
levels.
While useful, the expanding knowledge of the in vitro response
to NDV is insufﬁcient to understand the nature of the host re-
sponse to vNDV in vivo or to relate the underlying host immune
mechanisms to viral pathogenesis. Despite decades of research
characterizing pathogenesis of different isolates, little is known
about the molecular mechanisms of disease caused by NDV in
the host. Recently, global analysis of the host response to infection
in vivo with a vNDV strain from the 2002 outbreak in California
(CA02) characterized the early host response in chickens (Rue
et al., 2011). Using microarray technology, a strong transcriptional
host response in spleens of chickens at early times after infection
was demonstrated with the induction of groups of genes involved
in antiviral and pro-inﬂammatory cytokine responses. Multiple
genes were upregulated at 48 h.p.i. including, IFN-a, IFN-c, several
cytokines and chemokines, IFN effectors and inducible nitric oxide
synthase (iNOS). Many genes associated with an early innate host
response were induced by CA02 at 24 h.p.i., including the pro-
inﬂammatory cytokine IL-6, chemokine macrophage inﬂammatory
protein-3 alpha (MIP-3a), myxovirus resistance gene (Mx), lyso-
zyme, interferon-induced protein with tetratricopeptide repeats
5, ISG12-2, melanoma differentiation associated protein-5, and
IFN-c precursor. Several other markers of the innate immune re-
sponse to NDV that were not induced at 24 h.p.i. were upregulated
at 48 h.p.i., including iNOS, IL-1b, IL-18, IL-8 and IFN-c. The in-
creased transcription of iNOS was conﬁrmed by immunohisto-
chemistry in spleens and measured levels of nitric oxide in
serum, indicating functional protein formation. The signiﬁcant
upregulation of iNOS in spleens and NO in serum is a potentially
destructive innate response of chickens to NDV infection, but in
light of the robust replication and rapid mortality of this virus in
chickens, it seems quite possible that NO is contributing to mortal-
ity not recovery.
Finally, vNDV infection also induced expression of the antiviral
IFN effector genes, namely protein kinase R and 20-50-oligoadeny-
late synthetase (OAS). Other cytokines, including K203, ah221,
CXCL13/BCA-1, CCL21, and MIP-1b, were also upregulated follow-
ing NDV infection. Several of these cytokines are chemokines, most
notably MIP-3a and MIP-1b, which function to enhance cell-med-
iated responses by recruiting effector leukocytes. Other genes that
were signiﬁcantly induced by the CA02 infection are part of the in-
nate signaling processes, including regulator of G-protein signaling
1 (ADORA), suppressor of cytokine signaling (SOCS)-1 and -3, N-
myc, STAT interactor, STAT4 and IRF 1, 7 and 10.3. Antibody response to infection and vaccination with NDV
In addition to biosecurity and the culling of infected birds, vac-
cinations are a critical component to control ND (Marangon and
Busani, 2006; Seal et al., 2000). International and national vaccina-
tion control policies will depend on the factors affecting that sector
of poultry production, while keeping with the OIE regulations (OIE,
2012). The goal of vaccination is always sterilizing immunity, how-
ever, that has not yet been achieved with NDV vaccines. At best,
NDV vaccines induce an immune response that reduces or com-
pletely prevents clinical disease and mortality from ND, decreases
the amount of vNDV shed into the environment, and increases the
amount of virus needed to infect the vaccinated animal (Marangon
and Busani, 2006; Miller et al., 2009).
Herd immunity is another beneﬁcial consequence of a
successful vaccination program as it provides some protection to
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vaccinated ﬂock (Marangon and Busani, 2006). However, this out-
come is only achieved with ND when greater than 85% of the ﬂock
have hemagglutination inhibition (HI) antibody titers greater than
8 after two vaccinations (van Boven et al., 2008). Field results sug-
gest that only birds with HI titers greater than 16 after multiple
vaccinations will survive a vNDV challenge as 66% of the ﬂock suc-
cumbed with titers less than that (Kapczynski and King, 2005).
More commonly, HI levels of 32 or higher are what are typically
thought of being protective (Allan et al., 1978).
Mass application of live vaccines is often used due to the lower
cost and faster application time compared to having to administer
individual vaccines to each bird of a ﬂock (Senne et al., 2004). The
lentogenic B1 and LaSota vaccine strains of low virulence are com-
monly used worldwide, and can provide protection against vNDV if
the vaccines are viable, administered correctly to healthy birds and
time is allowed for an appropriate immune response to develop
prior to exposure to the challenge virus (Cornax et al., 2012; Dort-
mans et al., 2012; Kapczynski and King, 2005). Unfortunately, con-
ditions in the ﬁeld are often less than optimal with mass
application potentially reaching as little as 53% of the ﬂock when
the route of administration is spray and 60% when the route is
through the drinking water (Degefa et al., 2004). The presence of
immunosuppressive organisms can also render ineffective a proto-
col that is sound under experimental conditions (Perozo et al.,
2012). Indeed even the most efﬁcacious vaccine cannot induce an
immune response if the bird is immunosuppressed.
Inactivated vaccines are often administered to layers and breed-
ers to provide long lasting high antibody titers that can be passed
to offspring (Al-Garib et al., 2003b). However, withdrawal times
between vaccination and slaughter reduce the ability to use these
types of vaccines throughout the production period (Senne et al.,
2004). Inactivated vaccines are more expensive to produce, and re-
quire individual administration. Until recently the dogma is that
inactivated vaccines will not induce a mucosal immune response,
but a recent study demonstrated that both live and inactivated
NDV vaccines induced antibodies other than IgA, not only in serum,
but also in tracheal and intestinal washes (Chimeno Zoth et al.,
2008).
Because all NDV are in one serotype any NDV strain can be used
as a vaccine and all vaccines should prevent clinical disease and
death from ND. However, some studies have been demonstrated
that vaccines formulated with strains more similar to the challenge
virus can decrease the amount of challenge virus shed in oropha-
ryngeal swabs from vaccinated birds and potentially decrease the
number of birds that shed virus (Cho et al., 2008; Miller et al.,
2009, 2007; Xiao et al., 2012). These experiments demonstrate that
some NDV strains are more antigenic than others from varying HI
antibody titer levels to different antigens after equal amounts of
vaccines are administered. Testing the same hypothesis, using
additional experimental recombinant NDV strains, others have
found no difference in the shedding of vNDV in tracheal swabs
after challenge and maintain that the inadequate application of
NDV vaccines worldwide account for the current outbreaks and
spreading of vNDV ﬁeld strains (Dortmans et al., 2012). Due to
all NDV being one serotype, a vaccine formulated with a new strain
would not perform worse than a traditional strain and might pos-
sibly decrease the amount of vNDV shed into the environment
from the vaccinated birds. Considering that mass vaccine applica-
tions methods are necessary for commercial poultry, support for
newer NDV vaccines to provide better protection is needed.
In ovo vaccination at the time when eggs are moved from the
incubators to the hatcher is an attractive option for poultry pro-
ducers. Marek’s disease vaccines, infectious bursal disease vaccines
and fowl pox vaccines are commonly delivered at this time (day 18
or 19 of incubation) using egg injection systems (Williams andZedek, 2010). Unfortunately little progress has been made with
attenuating live NDV strains to give consistently reliable hatchabil-
ity results (Dilaveris et al., 2007; Kapczynski et al., 2012; Ramp
et al., 2012). However, the recombinant HVT (rHVT) platforms con-
taining the fusion (F) gene of NDV is promising for in ovo use
(Anonymous, 2010; Palya et al., 2012). For areas with endemic
vNDV other traditional vaccines may have to be delivered along
with the rHVT (Rauw et al., 2010). Unfortunately, while some HI
activity may be present the ELISA and HI assays cannot be used
to assess the immunity induced by these rHVT vaccines and efﬁ-
cacy is determined with mortality data. In ovo administration of
fowl pox (FP) vectored ND vaccines is also possible (Sharma
et al., 2002). These rHVT and FP vectored vaccines are advanta-
geous in that they do not cause respiratory disease after vaccina-
tion as live NDV vaccines may. Racing pigeons are often
vaccinated with killed ND vaccines formulated with inactivated a
PPMV-1 strain, which decreases the duration, incidence and
amount of virus shed after challenge, which is one of the goals of
vaccinating for any disease (Kapczynski et al., 2006). Even though
vaccinated birds infected with vNDV will shed virus after infection,
with vNDV ﬁrst shed in oral secretions peaking three to four days
post infection and cloacal shedding occurring later (Miller et al.,
2009), the goal of vaccination should be to decrease shedding
two to three logs compared to non-vaccinated animals (Miller
et al., 2007).
In the chicken, IgM, IgY (avian IgG equivalent) and IgA antibod-
ies are produced as part of the immune response (Jeurissen et al.,
2000). Antibodies are detected at the site of infection and in the
blood starting at six days after infection or live virus vaccination
and peaks 21–28 days after infection (Al-Garib et al., 2003a). Anti-
bodies neutralize the ND virus particles by binding and preventing
attachment of the virus to host cells (Al-Garib et al., 2003a).
Approximately 30% of the IgY and 1% of the IgM and IgA antibodies
present in the hen’s plasma will passively transfer to the offspring
and if the NDV antibody levels are high enough can provide protec-
tion until the levels fall below a protective level (Hamal et al.,
2006). This maternal antibody can interfere with live vaccination
by neutralizing the vaccine virus (Giambrone and Closser, 1990;
Westbury et al., 1984).
Adjuvants to improve the immune response of NDV vaccines
were initially focused on inactivated vaccines (Mitchell andWalker,
1951; Stone and Xie, 1990; Yin et al., 2006), but now include sub-
stances to favorably modulate the immune response from live
NDVvaccines (Hilton et al., 2002; Zhanget al., 2007). Dietary supple-
ments are commonly tested because the compoundsmay be locally
available and/or because the compound maybe easily added to the
diet to improve the immunity after vaccination. Lactobacillus-based
probiotics have been shown to improve humoral immunity to live
NDV vaccines in birds under heat stress (Sohail et al., 2010). Antibi-
oticsmay be added to water at the time of vaccination to provide an
undeﬁned beneﬁt to the birds (Khalifeh et al., 2009). However,when
antibiotics are evaluated for their ability to positively potentiate the
humoral immune response toNDVvaccines, typically they are found
to decrease the response (Khalifeh et al., 2009) or not signiﬁcantly
improve the response (Munir et al., 2007). Astragalus polysaccha-
rides commonly used in Chinese medicines to enhance the immune
response demonstrated slight improvements in the humoral im-
mune response to NDV vaccination with or without sulfation
(Huang et al., 2008). Glycyrrhetinic acid liposomes demonstrated a
signiﬁcantly improved humoral response to NDV vaccination 21–
42 days after vaccination (Zhao et al., 2011).
4. Cellular immunity induced by NDV
Cell-mediated immunity (CMI) is speciﬁc adaptive immunity
mediated by T lymphocytes and has been suggested to be an
D.R. Kapczynski et al. / Developmental and Comparative Immunology 41 (2013) 447–453 451important factor to the development of protection in chickens vac-
cinated against NDV and contribute to viral clearance (Cannon and
Russell, 1986; Ghumman et al., 1976; Marino and Hanson, 1987;
Merz et al., 1981; Perey et al., 1975; Sharma, 1999). The subsets
of T lymphocytes, including cytokine-secreting CD4+ T helper cells,
and CD8+ cytotoxic T lymphocytes (CTL), constitute the principal
cells of the CMI response. Unlike antibody measurement via ELISA
or HI, testing for CMI is more labor intensive and requires more
skilled procedures. Tests for CMI include induction of IFN-c from
stimulated lymphocytes, cellular response to recall antigen or
mitogen through proliferation, ﬂow cytometry of lymphocytes,
and levels of cytotoxicity observed by NDV speciﬁc CD8+ T cells
to NDV-infected target cells. While the ability to measure avian
CMI responses has steadily increased over the last few years, few
studies have examined the induction and role of cell-mediated
immunity in avian species against NDV.
Cell-mediated stimulation following NDV infection is detected
as early as 2–3 days post infection (Ghumman et al., 1976). More
recent studies also conﬁrmed CMI responses to NDV may be de-
tected shortly after vaccination with a live NDV vaccine (Reynolds
and Maraqa, 2000). In those studies, chickens with CMI speciﬁc for
NDV, determined by blastogenesis microassay with inactivated
NDV, were not protected from lethal challenge in the absence of
HI antibodies. However birds with NDV-speciﬁc antibodies were
shown to be protected. The results indicate that antibodies are
the key modulators of protection, but that CMI likely contributes
to decrease viral shedding through target killing of NDV infected
cells (Russell et al., 1997).
Subsequent studies have compared CMI responses between
birds receiving live versus inactivated NDV vaccines. In one study,
measurement of IFN-c by ELISA and proliferation to NDV from
splenocytes obtained from chickens receiving live or inactivated
NDV vaccines were compared (Lambrecht et al., 2004). Results
indicate increased CMI with the live NDV vaccination. Whereas live
NDV stimulates both major histocompatibility complex (MHC)
class I (CD8+) and II (CD4+) presentation in the host, CMI derived
from inactivated NDV vaccines take longer to develop and are
not as robust. CMI derived from inactivated vaccines appear to
be stimulated through CD4+ lymphocytes and MHC-class II presen-
tation that drive antibody formation likely through directed cyto-
kine secretion. Additional studies examined the role of vaccine
virulence in CMI. Not surprisingly, the virulence of the virus ap-
pears to play a role in CMI stimulation. Rauw et al., demonstrated
an earlier and shorter CMI induced by a less virulent NDV vaccine
strain, compared to a stronger and longer CMI mediated by a more
virulent vaccines strain (Rauw et al., 2009). Thus, the more virulent
strain persisted longer in the bird and therefore was able to in-
crease magnitude and duration of CMI.
More recently, use of nanotechnology was employed to exam-
ine the adjuvant effect on inactivated NDV vaccines in chickens.
In these studies, the addition of calcium phosphate (CP) was ap-
plied to inactivated NDV vaccines and the resulting CMI compared
to that induced by live NDV vaccination (Koppad et al., 2011). Re-
sults indicate CMI induced with CP coupled to inactivated NDV
achieved similar levels as those obtained with the live NDV vac-
cine. The results demonstrate that at 1-week post vaccination birds
receiving CP signiﬁcantly increased CMI to NDV compared to live
NDV vaccinated birds. However, comparison of potency of the vac-
cines was not compared using direct challenge such that any posi-
tive contribution to protection through decreased viral shedding
was not determined.
Taken together, recent advances in detection of CMI following
live NDV vaccination make it apparent that while antibodies re-
main the primary mechanism of protection against virulent NDV,
the contributions of CMI are important considerations in the face
of ﬁeld challenge. As new vaccine strategies are employed toprotect poultry against vNDV it appears obvious that combining
both arms of the adaptive immune response provide the best pro-
tection of birds and decrease the risk of transmission to susceptible
animals.5. Conclusion
NDV is an economically important and frequently isolated
worldwide pathogen whose listed status with OIE marks its impor-
tance to both commercial poultry producers and poultry trading
countries. Control of vNDV through use of vaccines is regularly
and routinely practiced by all major poultry companies to provide
immunological protection against disease. Our understanding of
protective immunity against NDV is largely based on the produc-
tion of antibodies directed viral proteins involved with attachment
and fusion. However, our knowledge of the avian immune re-
sponse to NDV is incomplete. While NDV exists as a single sero-
type, recent genotyping of vNDV isolates indicates that vaccines
viruses established in the 1950s may be losing efﬁcacy against
these new viruses of the 21st century. There is a speciﬁc need for
renewed research in immunity induced by NDV in poultry. One
of the current challenges is to identify the molecular mechanisms
of innate immunity that leads to an enhanced protection from
infection and results in decreased shedding and transmission. Con-
versely, what are the deleterious effects of an unbalanced or unreg-
ulated innate immune response on pathogenesis, and how are viral
factors contributing to this? Furthermore, the contributions of CMI
to the overall protection against NDV, while undeniable, are still
largely undeﬁned. The cell types and epitopes involved need to
be better characterized so that new vaccines can be designed to
take advantage of this knowledge. With the advent of the genomics
age, including the compete sequencing of the chicken genome,
knowledge of structure and function of avian immune response
elements involved in protective immunity to NDV can now be ex-
plored and tested. Elucidation of the immune response to NDV re-
mains a top priority for the development of better control
strategies in the face of reoccurring outbreaks.Acknowledgements
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